arrow
M

Min Yuen Teo

Memorial Sloan Kettering Cancer Center
H指数:28
被引数:4,595

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer

通过调节PPARγ通路上调NECTIN4,并增强膀胱癌中嵌合抗原受体(CAR)T细胞疗法。Nat. Commun. 16 (1), 8215

2025-09-100
OAAI
Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study

血浆优先下一代测序在爱尔兰新诊断的晚期非小细胞肺癌患者中的临床获益与成本:PLAN研究

2025-06-170
PRE
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma☆

接受过恩普替尼韦汀治疗后的转移性尿路上皮癌患者中,沙西妥珠单抗戈维他胺的实时临床疗效☆

2025-06-010
OA
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma

临床结局、基因组异质性及不同组织学亚型的尿路上皮癌的治疗考量

2025-04-260
PRE
Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications
2024-10-011
PRE
Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

接受恩沃利单抗(EV)单药治疗且未出现疾病进展的转移性尿路上皮癌(mUC)患者的临床结局

2024-09-010
PRE
Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution

联盟A031501:AMBASSADOR研究,评估辅助治疗中帕博利珠单抗(Pembro)在肌肉浸润性尿路上皮癌(MIUC)与观察(Obs)相比的扩展随访无病生存期(DFS)结果及转移性(met)疾病复发的分布

2024-09-010
PRE
Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors
2023-12-010
PRE
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation (vol 13, 6575, 2022)
2022-12-231
OAAI
Genomic heterogeneity as a barrier to precision oncology in urothelial cancer
2022-12-0121
OAAI
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
2022-11-0220
OAAI
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma (vol 124, pg 1214, 2021)
2022-02-101
OA
Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma
2021-09-011
OAAI
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma (vol 78, pg 907, 2020)
2021-05-010
PRE
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma
2021-02-014
OA